Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863410 | 0.87 | MEN1 (0.37) | MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL5863154 | 0.87 | CYP2D6 (0.49) | MEN1KMT2ACYP2D6CYP3A4CYP2C9 | |
| SCHEMBL5863176 | 0.85 | SPPL2A (0.41) | MEN1KMT2A | |
| SCHEMBL5863343 | 0.83 | CHRM5 (0.36) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL2582577 | 0.81 | CYP2D6 (0.47) | CYP2D6CYP3A4CYP2C9ALDH1A1CYP2C19 | |
| SCHEMBL5403917 | 0.80 | ALDH1A1 (0.41) | KMT2AALDH1A1LMNAMAPTPOLB | |
| SCHEMBL5863086 | 0.79 | ACR (0.45) | MEN1KMT2ACYP2D6CYP3A4CYP2C9 | |
| SCHEMBL5863089 | 0.79 | MMP2 (0.42) | ALDH1A1LMNAMAPTPOLB | |
| SCHEMBL8445408 | 0.77 | ALDH1A1 (0.38) | KMT2AALDH1A1HSD17B10LMNAPOLB | |
| Bromide SCHEMBL4972241 | 0.76 | MEN1 (0.35) | MEN1KMT2ACYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264483-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-11-23 | — | — | US | disclosed |
| US-7045518-B2 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040147758-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2004-07-29 | — | — | US | disclosed |
| EP-1052250-B1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | SEARLE & CO (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6667307-B2 | HIV protease | G.D. SEARLE & CO. | 2003-12-23 | — | — | US | disclosed |
| US-20030191166-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2003-10-09 | — | — | US | disclosed |
| US-6380188-B1 | FOR INHIBITING HUMAN IMMUNODEFICIENCY VIRUS PROTEASE | G. D. SEARLE & CO. | 2002-04-30 | — | — | US | disclosed |
| EP-0813519-B1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 2001-05-09 | — | — | EP | disclosed |
| US-6169085-B1 | A VIRICIDE FOR PREVENTING AND TREATING RETROVIRAL INFECTION OR THE SPREAD OF A RETROVIRUS, INHIBITING REPLICATION OF A RETROVIRUS AND TREATING AIDS | G. D. SEARLE & COMPANY | 2001-01-02 | — | — | US | disclosed |
| EP-1052250-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2000-11-15 | — | — | EP | disclosed |
| US-5985870-A | TREATING HIV INFECTIONS | G.D. SEARLE & CO. (US) | 1999-11-16 | — | — | US | disclosed |
| WO-1996028418-A1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147758-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, PRSS1 | MEN1 4502/4885KMT2A 746/4885CYP2D6 3131/4885 |
| US-20060264483-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, PRSS1 | MEN1 4502/4885KMT2A 746/4885CYP2D6 3131/4885 |
| US-20030191166-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, PRSS1 | MEN1 4502/4885KMT2A 746/4885CYP2D6 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.